Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Amgen (AMGN – Research Report) today. The company’s shares closed ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares. Competitor Biohaven’s (BHVN) Phase 3 trial in ...

Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of ...

Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...

"ABBV's pain is BMY's gain," Truist Securities analyst Srikripa Devarakonda said in a note released Tuesday. "We see this as a negative for AbbVie (ABBV, Buy) and a positive for Bristol (BMY ...

Operator? Operator: Thank you. [Operator Instructions]. Our first question comes from Srikripa Devarakonda Truist Securities. Your line is open. Srikripa Devarakonda: Hey, guys. Thank you so much ...

Thanks for taking my questions. Operator: Thank you. The next question comes from Srikripa Devarakonda with Truist. You may proceed. Srikripa Devarakonda: Hey, guys. Thank you so much for taking ...